top of page

®

Foveal LLP Independent Investment Research Foveal Research

Independent Investment Research

Search

NOVN/AMGN: Cholesterol-busting Lipoprotein (a) drugs likely to lead to new multibillion cardiovascular breakthrough

Dec 11, 2024

NOVN lipoprotein (a) cholesterol-lowering pelacarsen is likely to be the first cardiovascular breakthrough in decades by reducing an alternative cholesterol molecule to prevent heart attacks, with AMGN, LLY and SLN close behind...

Lipoprotein

Comments

Focus Research

JNJ/PTGX: JNJ2113: Concerns over upcoming (Q1) oral IL23 ANTHEM trial in Ulcerative Colitis

JNJ/PTGX: JNJ2113: Concerns over upcoming (Q1) oral IL23 ANTHEM trial in Ulcerative Colitis

NOVN: Consensus missing large Fabhalta upside

NOVN: Consensus missing large Fabhalta upside

NOVN/AMGN: Cholesterol-busting Lipoprotein (a) drugs likely to lead to new multibillion cardiovascular breakthrough

NOVN/AMGN: Cholesterol-busting Lipoprotein (a) drugs likely to lead to new multibillion cardiovascular breakthrough

ADC: AZN Dato overall survival misses underscores our long held concerns for ADC's in 1L Lung

ADC: AZN Dato overall survival misses underscores our long held concerns for ADC's in 1L Lung

WCLC: Hold you HARMONis: Keytruda safe from Summit

WCLC: Hold you HARMONis: Keytruda safe from Summit

NOVN/ROG: Fabulous Fabhalta halts Piasky blue skies

NOVN/ROG: Fabulous Fabhalta halts Piasky blue skies

ADCs @ ASCO: concerns over Dato-DXd in 1L Lung; GILD 2L OS as bad as AZN; SKB high ORR in unusual trial

ADCs @ ASCO: concerns over Dato-DXd in 1L Lung; GILD 2L OS as bad as AZN; SKB high ORR in unusual trial

MRNA/MRK: ASCO cancer vaccine data does not address pre-treatment imbalances that may be driving result

MRNA/MRK: ASCO cancer vaccine data does not address pre-treatment imbalances that may be driving result

ROG/SRPT: Duchenne EMBARK likely enought to lessen age restrictions

ROG/SRPT: Duchenne EMBARK likely enought to lessen age restrictions

AZN/ROG: Roche/AZN: SERDs restrict or fail

AZN/ROG: Roche/AZN: SERDs restrict or fail

Recent Reseacrh

JNJ/PTGX: JNJ2113: Icotrokinra ANTHEM-Ulercative Colitis efficacy similar to oral competitors

JNJ/PTGX: JNJ2113: Concerns over upcoming (Q1) oral IL23 ANTHEM trial in Ulcerative Colitis

NOVN: Consensus missing large Fabhalta upside

NOVN: Consensus missing large Fabhalta upside

NOVN/AMGN: Cholesterol-busting Lipoprotein (a) drugs likely to lead to new multibillion cardiovascular breakthrough

NOVN/AMGN: Cholesterol-busting Lipoprotein (a) drugs likely to lead to new multibillion cardiovascular breakthrough

ADC: AZN Dato overall survival misses underscores our long held concerns for ADC's in 1L Lung

ADC: AZN Dato overall survival misses underscores our long held concerns for ADC's in 1L Lung

WCLC: Hold you HARMONis: Keytruda safe from Summit

NOVN/ROG/IONS/CALTX/AZN: Factor B lacking the X Factor in IgAN

NOVN/ROG: Fabulous Fabhalta halts Piasky blue skies

ADCs @ ASCO: concerns over Dato-DXd in 1L Lung; GILD 2L OS as bad as AZN; SKB high ORR in unusual trial

ADCs @ ASCO: concerns over Dato-DXd in 1L Lung; GILD 2L OS as bad as AZN; SKB high ORR in unusual trial

MRNA/MRK: ASCO cancer vaccine data does not address pre-treatment imbalances that may be driving result

Archive

Search By Tags

Follow Us on:

Bloomberg: FOVL <go>

ThomsonReuters

FactSet

Captial IQ

bottom of page